Average Co-Inventor Count = 8.52
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (20 from 2,405 patents)
2. Protagonist Therapeutics, Inc. (2 from 32 patents)
3. Janssen Pharmaceutica Nv (1 from 2,076 patents)
4. Janssen Biotech, Inc. (1 from 410 patents)
5. Mochida Pharmaceutical Co., Ltd. (1 from 227 patents)
6. Merck Canada Inc. (1 from 40 patents)
7. Kallyope, Inc. (1 from 6 patents)
23 patents:
1. 12478617 - Lipidated peptide inhibitors of interleukin-23 receptor
2. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
3. 12281114 - NK3 modulators and uses thereof
4. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
5. 11939361 - Compositions of peptide inhibitors of Interleukin-23 receptor
6. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
7. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
8. 10239863 - Factor XIa inhibitors
9. 10214512 - Factor XIA inhibitors
10. 10123995 - Factor XIa inhibitors
11. 10093683 - Factor XIa inhibitors
12. 10081617 - Factor XIa inhibitors
13. 9944643 - Factor XIa inhibitors
14. 9809545 - Factor XIa inhibitors
15. 9676723 - Factor XIa inhibitors